drugset / Trial / NCT03654833
Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant Mesothelioma
Phase 2
Unknown
186 enrolled
University of Leicester
BerGenBio ASA · collabBritish Lung Foundation · collabClovis Oncology, Inc. · collabEli Lilly and Company · collabGlaxoSmithKline · collabMerck Sharp & Dohme LLC · collabRoche Pharma AG · collabThe Christie NHS Foundation Trust · collabUniversity Hospitals, Leicester · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
MiST is a British Lung Foundation funded, University of Leicester Study, a multi-arm stratified therapy based clinical trial for patients with relapsed mesothelioma. The goal of MiST is to enable acceleration of novel, effective personalised therapy as a basis for improving survival outcomes for patients with mesothelioma.
Timeline
- Start
- 2019-01-28
- Primary completion
- 2023-10-31
- Completion
- 2023-10-31
Publications
- Fennell DA, King A, Mohammed S, Greystoke A, Anthony S, Poile C, Nusrat N, Scotland M, Bhundia V, Branson A, Brookes C, Darlison L, Dawson AG, Gaba A, Hutka M, Morgan B, Bajaj A, Richards C, Wells-Jordan P, Thomas A; MiST2 study group. Abemaciclib in patients with p16ink4A-deficient mesothelioma (MiST2): a single-arm, open-label, phase 2 trial. Lancet Oncol. 2022 Mar;23(3):374-381. doi: 10.1016/S1470-2045(22)00062-6. Epub 2022 Feb 11.
- Fennell DA, King A, Mohammed S, Branson A, Brookes C, Darlison L, Dawson AG, Gaba A, Hutka M, Morgan B, Nicholson A, Richards C, Wells-Jordan P, Murphy GJ, Thomas A; MiST1 study group. Rucaparib in patients with BAP1-deficient or BRCA1-deficient mesothelioma (MiST1): an open-label, single-arm, phase 2a clinical trial. Lancet Respir Med. 2021 Jun;9(6):593-600. doi: 10.1016/S2213-2600(20)30390-8. Epub 2021 Jan 27.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abemaciclib | Small molecule | 200 mg | Oral |
| Subject | Atezolizumab | Monoclonal antibody | 1200 mg | Intravenous |
| Subject | Bemcentinib | Small molecule | 200 mg | — |
| Subject | Bevacizumab | Monoclonal antibody | 15 mg/kg | Intravenous |
| Subject | Dostarlimab | Monoclonal antibody | 1000 mg | — |
| Subject | Niraparib | Small molecule | 200 mg | — |
| Subject | Niraparib | Small molecule | 300 mg | — |
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |
| Subject | Rucaparib | Small molecule | 600 mg | Oral |